A Phase 1, Open-Label, Parallel-Group, Adaptive Single-dose Study to Evaluate the Pharmacokinetics of GS-9883 in Subjects With Normal and Impaired Renal Function

Trial Profile

A Phase 1, Open-Label, Parallel-Group, Adaptive Single-dose Study to Evaluate the Pharmacokinetics of GS-9883 in Subjects With Normal and Impaired Renal Function

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2015

At a glance

  • Drugs Bictegravir (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 21 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Aug 2015 Planned End Date changed from 1 Mar 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.
    • 24 Aug 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top